Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	123.58	105.6	145.65	123.55	293.83	140.41
Short-Term Investments	196.05	264.93	400.58	516.6	320.97	472.21
Cash & Short-Term Investments	319.62	370.53	546.22	640.15	614.79	612.62
Cash Growth	-27.45%	-32.17%	-14.67%	4.13%	0.36%	40.49%
Prepaid Expenses	8.58	9.07	8.46	11.14	11.49	4.93
Total Current Assets	328.2	379.59	554.69	651.3	626.29	617.55
Property, Plant & Equipment	56.63	72.94	142.32	166.27	166.64	124.06
Long-Term Investments	19	32.01	48.51	115.04	330.53	163.44
Other Long-Term Assets	4.13	6.31	4.52	4.96	3.95	3.24
Total Assets	407.97	490.86	750.03	937.56	1,127	908.28
Accounts Payable	2.57	5.37	4.82	3.92	3.21	9.4
Accrued Expenses	29.31	29.37	20.36	21.14	22.36	17.84
Current Portion of Leases	-	7.97	6.27	4.53	1.17	3.62
Current Unearned Revenue	-	-	-	-	4.99	6.1
Other Current Liabilities	-	11.08	3.07	7.44	15.01	12.34
Total Current Liabilities	31.88	53.79	34.52	37.03	46.74	49.29
Long-Term Leases	44.29	50.99	56.89	63.17	66.65	50.96
Long-Term Unearned Revenue	-	-	-	-	79.67	89.07
Other Long-Term Liabilities	2.68	3.25	3.66	4.11	4.57	0.53
Total Liabilities	78.84	108.04	95.08	104.31	197.62	189.84
Common Stock	0	0.03	0.03	0.03	0.02	0
Additional Paid-In Capital	1,808	1,728	1,657	1,608	1,516	41.36
Retained Earnings	-1,479	-1,345	-1,002	-767.48	-584.36	-334.14
Comprehensive Income & Other	0.2	0.29	-0.09	-7.6	-1.62	0.26
Total Common Equity	329.12	382.82	654.95	833.25	929.79	-292.53
Shareholders' Equity	329.12	382.82	654.95	833.25	929.79	718.44
Total Liabilities & Equity	407.97	490.86	750.03	937.56	1,127	908.28
Total Debt	44.29	58.97	63.17	67.7	67.82	54.57
Net Cash (Debt)	275.34	324.57	499.56	642.57	830.51	638.04
Net Cash Growth	-31.52%	-35.03%	-22.25%	-22.63%	30.16%	43.84%
Net Cash Per Share	17.81	24.83	39.81	52.01	122.21	962.50
Filing Date Shares Outstanding	21.22	14.76	12.7	12.48	12.14	0.89
Total Common Shares Outstanding	19.29	14.74	12.7	12.48	12.14	0.78
Working Capital	296.32	325.81	520.17	614.27	579.55	568.26
Book Value Per Share	17.06	25.97	51.58	66.78	76.61	-375.76
Tangible Book Value	329.12	382.82	654.95	833.25	929.79	-292.53
Tangible Book Value Per Share	17.06	25.97	51.58	66.78	76.61	-375.76
Machinery	-	39.03	35.85	34.33	29.03	17.99
Construction In Progress	-	0.24	0.13	4.15	10.58	55.71
Leasehold Improvements	-	79.61	118.32	116.93	95	8.45

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q